Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
BUSINESS
300 Million Yen Fine Sought for Toho Too, Court Decision Due June 2: Bid-Rigging Trial
Tokyo prosecutors sought a fine of 300 million yen to be levied on major wholesaler Toho Pharmaceutical in a high-profile bid-rigging trial on April 28, the day after they did the same for another Big 4 distributor Suzuken. Toho, Suzuken,…
To read the full story
Related Article
- Mediceo Gets 6-Month Suspension from National Hospital Organization Bids
April 18, 2022
- Mediceo Dodged Charges and FTC Penalties, but Still Barred from JCHO Bids
April 12, 2022
- 3 Wholesalers Ordered to Pay 420 Million Yen in Surcharge over Bid-Rigging; JCHO to Suspend Mediceo Too
March 31, 2022
- FTC to Slap 3 Wholesalers with 420 Million Yen Surcharges over Bid-Rigging
February 7, 2022
- Guilty Rulings for 3 Wholesalers, Employees Now Final and Binding: Bid-Rigging Trial
July 19, 2021
- 3 Major Wholesalers, 7 Employees Found Guilty in Bid-Rigging Trial
July 2, 2021
- 300 Million Yen Fine Sought for Alfresa Too, Verdict on June 30: Bid-Rigging Trial
May 13, 2021
- Prosecutors Seek 300 Million Yen Fine for Suzuken, Jail Terms for Employees: Bid-Rigging Trial
April 28, 2021
- 3 Indicted Wholesalers Barred from JCHO Bids for 2 Years: Bid-Rigging Scandal
December 14, 2020
- (Update) Criminal Charges Sought against 3 Wholesalers over Bid-Rigging, Mediceo Excluded
December 10, 2020
- Criminal Charges Sought against 3 Wholesalers over Bid-Rigging, Mediceo Excluded
December 9, 2020
- JPWA Raided Too over Big 4 Wholesalers’ Bid-Rigging Scandal
October 16, 2020
- Big 4 Wholesalers Now Suspected to Have Rigged Drug Prices in 2016 Too
October 14, 2020
- Big 4 Wholesalers Raided Again over Suspected Bid-Rigging
October 13, 2020
- JCHO Hospitals to Switch from Joint to Separate Bidding for Drug Purchases after Bid-Rigging Scandal
May 21, 2020
- “Tender Process Needs to Be Improved” in Response to Bid-Rigging Scandal by Top 4 Wholesalers: Hospital Management Advisor
February 25, 2020
- MHLW Bureau Chief Says Delay Would Be Inevitable to Revise Drug Distribution Guidelines as Bid-Rigging Probe Continues
January 17, 2020
- Big 4 Wholesalers Faced Wrath of FTC for Allocating Priority Drug Categories before Bidding
December 6, 2019
- Wholesalers’ Bid-Rigging Scandal Might Have Been Exposed via Leniency Program, Further Cases Could Be Laid Bare: Lawyer
December 6, 2019
- Scandal-Hit JPWA Likely to Pass on Chuikyo’s Industry Hearing on Dec. 6
December 4, 2019
- Ryukaikon’s Dec. 9 Meeting Likely to Be Put Off in Wake of Bid-Rigging Scandal
December 3, 2019
- Stakeholders Rap Big 4 Wholesalers for Bid-Rigging Charges, Say Scandal Shutters Trust in Drug Price Surveys
November 29, 2019
- Big 4 Drug Wholesalers Raided on Bid-Rigging Charges
November 28, 2019
BUSINESS
- Nihon Servier Files Glioma Drug Vorasidenib in Japan
December 25, 2024
- Sumitomo’s Gemtesa Expands Label in US to OAB Patients with BPH
December 25, 2024
- Daiichi, AZ Pull EU Dato-DXd Filing for Lung Cancer
December 25, 2024
- Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
- Increased Off-Year Pressure on LLPs Would Only Exacerbate Supply Crunch: Industry Officials
December 24, 2024
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…